Tempus AI, a leading company in applying AI to precision medicine, has published a study validating its investigational human leukocyte antigen (HLA) loss of heterozygosity (LOH) assay in the journal npj Precision Oncology. This test identifies patients with solid tumors who may benefit from targeted therapies based on specific HLA-LOH events.
The study confirmed the assay’s accuracy in detecting HLA-LOH in clinical samples. Tempus collaborated with A2 Biotherapeutics to demonstrate the feasibility of identifying and enrolling HLA-LOH patients in clinical trials using data from routine diagnostic tests.
The assay’s significance lies in its application in clinical trials involving cell therapy for solid tumors. It also has implications for wider precision medicine, complementing other established biomarkers. The test is an investigational device not currently available for clinical use but has received Breakthrough Device Designation from the FDA.
Tempus is advancing precision medicine through its large library of multimodal data and AI-enabled solutions. By making data accessible and useful, Tempus empowers physicians to deliver personalized care and facilitates the discovery and delivery of optimal therapeutics. The company’s goal is to enable each patient to benefit from the accumulated knowledge and experiences of others.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.